12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine

Category Primary study
JournalThe Lancet. Infectious diseases
Year 2024
This article has no abstract
Epistemonikos ID: ed4005080d5f5c7bc9eda0b562e59c7ca47a88ed
First added on: Oct 11, 2024